Skip to main content
Clinical Trials/NCT02899624
NCT02899624
Unknown
Not Applicable

Whole Exome Sequencing in Bicuspid Aortic Valve Patients

Assistance Publique Hopitaux De Marseille1 site in 1 country427 target enrollmentJanuary 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bicuspid Aortic Valve
Sponsor
Assistance Publique Hopitaux De Marseille
Enrollment
427
Locations
1
Primary Endpoint
number of genetic abnormalities
Last Updated
9 years ago

Overview

Brief Summary

Bicuspid aortic valve (BAV), congenital anomaly present in 2% of the population, is defined by the presence of two sigmoid valves instead of three. It is conventionally associated with histological abnormalities of the wall of the ascending aorta, risk factors of aortic dystrophy observed in 50% of cases, and dissection. Long considered an accident of development, the discovery of mutations in the NOTCH1 gene in 2 families alternating BAV and aortic dystrophy suggests the existence of a genetic predisposition and a common genetic origin for these two pathologies.

Data on the genetic basis of the BAV are still limited, but the existence of a large phenotypic diversity suggests the involvement of other genes. The establishment of large collections of DNA will allow great advances in this field.

The purpose of this project is to confirm the existence of a genetic determinism at the origin of the BAV with or without dystrophy of non syndromic ascending aorta, identifying genetic defects associated with the presence of a BAV in a series of candidate genes.

Registry
clinicaltrials.gov
Start Date
January 2014
End Date
January 2018
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • bicuspid aortic valve, confirmed by transthoracic or transesophageal echocardiography
  • With or without an aneurysm of the ascending thoracic aorta nonsyndromic

Exclusion Criteria

  • aortic syndromic pathology
  • antecedent of acute articular rhumatism

Outcomes

Primary Outcomes

number of genetic abnormalities

Time Frame: 3 years

Study Sites (1)

Loading locations...

Similar Trials